Photo of Gabriela S. Hobbs,  MD

Gabriela S. Hobbs, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1124
Fax: (617) 724-2525

Gabriela S. Hobbs, MD

Massachusetts General Hospital


  • Assistant Professor, Medicine, Harvard Medical School
  • Clinical Director, Leukemia, Massachusetts General Hospital


Research Abstract

My primary clinical and research focus is in advancing the care of patients with myeloproliferative neoplasms (MPN). My primary clinical objective is to continue to develop a panel of patients with MPN from local and regional referrals. The goal of my research is to design and implement clinical trials for patients with MPNs with a significant translational component through collaborations with laboratory investigators.

In August of 2014 I joined the Leukemia Service at Massachusetts General Hospital where I have established a MPN clinical and research program. From a clinical perspective, I routinely receive referrals from across the northeast and have a strong referral network; this has allowed me to develop a panel that consists primarily of MPN patients. From a research perspective, I lead the MPN clinical trials at MGH, all of which include a strong translational component based. The investigator-initiated studies for which I am the principal investigator include- A phase II, multicenter study, of ruxolitinib before, during and after transplant for patients with myelofibrosis (Protocol 17-569). A phase I study of Regorafenib for patients with advanced myeloid neoplasms (Protocol 16-464). A phase II, multicenter study utilizing ruxolitinib for maintenance after transplant for older patients with AML (Protocol 17-273). A phase II, multicenter study investigating the use of pembrolizumab for myelofibrosis (Protocol 17-480). In addition, I am the site PI for all pharmaceutical sponsored studies in MPN at MGH.

In addition to clinical trials work, I collaborate with Dr. Ann Mullally in translational research utilizing samples from the above-mentioned trials. This work includes defining the role of genetic mutations in predicting post- allogeneic hematopoietic stem cell transplantation (SCT) outcomes in myelofibrosis patients utilizing samples from protocol 17-569. In addition, we are investigating the role of immune dysregulation and immunotherapy in patients with MPN. This research utilizes samples of patients collected from my clinic as well as samples from a clinical trial utilizing the checkpoint inhibitor, Pembrolizumab in patients with Myelofibrosis.

Ultimately, my goal is to continue to grow a multidisciplinary MPN research program focused on providing high quality care to patients with MPNs, and to develop new treatment options for patients with MPN based on sound pre-clinical rationale, while strengthening collaborations with investigators across the Dana Farber Harvard Cancer Center and across the country.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes J, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey E, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Goekbuget N, Gotlib JR, Hellström-Lindberg E, Hobbs G, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre EA, Malcovati L, Mullighan CG, Niemeyer CM, Odenike O, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer C, Schmitt-Graeff A, Shimamura A, Sierra J, Stock W, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood 2022. PubMed
  • Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Sci Transl Med 2022; 14:eaba4380. PubMed
  • Venkataraman V, Bales JR, Signorelli J, Hobbs GS. Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors. J Oncol Pharm Pract 2022. PubMed
  • How J, Gallagher KME, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia 2022; 36:1176-1179. PubMed
  • Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol 2022; 107:14-19. PubMed
  • Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, McGreggor K, Macrea M, Burke M, Behnam T, Som T, Ramos A, Vartanian M, Lombardi Story J, Connolly C, Blonquist T, Neuberg D, Fathi A. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Leuk Lymphoma 2022. PubMed
  • Nardi V, McAfee SL, Dal Cin P, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Foster J, Fathi AT, Hock H. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist 2022; 27:82-86. PubMed
  • Vaughn DM, Johnson PC, Jagielo AD, Topping CEW, Reynolds MJ, Kavanaugh AR, Webb JA, Fathi AT, Hobbs G, Brunner A, O'Connor N, Luger S, Bhatnagar B, LeBlanc TW, El-Jawahri A. Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. J Palliat Med 2021. PubMed
  • Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol 2021. PubMed
  • How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS, Connors JM. Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J 2021; 11:176. PubMed
  • Anandappa AJ, Hobbs GS, Dey BR, El-Jawahri A, Frigault MJ, McAfee SL, O'Donnell PV, Spitzer TR, Chen YB, DeFilipp Z. Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist 2021. PubMed
  • Amonoo HL, LeBlanc TW, Kavanaugh AR, Webb JA, Traeger LN, Jagielo AD, Vaughn DM, Elyze M, Longley RM, Fathi AT, Hobbs GS, Brunner AM, O'Connor NR, Luger SM, Gustin JL, Bhatnagar B, Horick NK, El-Jawahri A. Posttraumatic stress disorder (PTSD) symptoms in patients with acute myeloid leukemia (AML). Cancer 2021. PubMed
  • Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, Kamaz B, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Camargo FD, Michor F, Mullally A, Cortes-Ciriano I, Hormoz S. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell 2021. PubMed
  • El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol 2021; 7:238-245. PubMed
  • Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv 2020; 4:3136-3140. PubMed
  • Signorelli J, Lei M, Lam J, Jalbut M, Amrein PC, Fathi AT, Hobbs G, Hock H, McAfee SL, Letourneau AR, Narayan R, Brunner A. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clin Lymphoma Myeloma Leuk 2020. PubMed
  • Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol 2020. PubMed
  • Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O, Yacoub A, Moliterno A, Yang A, Braunstein E, Gerds AT, Hobbs GS, Winton EF, Goel S, Wadleigh M, Tremblay D, Moshier E, Mascarenhas J. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clin Lymphoma Myeloma Leuk 2020. PubMed
  • Signorelli J, Luk S, Tavares E, Hobbs GS. Antiemetic prophylaxis for induction chemotherapy in patients with acute myeloid leukemia. J Oncol Pharm Pract 2020. PubMed
  • Jan M, Grinshpun DE, Villalba JA, Dal Cin P, Sykes DB, Iafrate AJ, Ebert BL, Hobbs GS, Nardi V. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Adv 2020; 4:445-448. PubMed
  • Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv 2020; 4:106-111. PubMed
  • How J, Leiva O, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Zwicker JI, Fogerty AE, Hobbs GS. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res 2020; 98:106459. PubMed
  • How J, Hobbs GS. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic. J Natl Compr Canc Netw 2020; 18:1271-1278. PubMed
  • Strohbehn S, Seethapathy H, Rusibamayila N, Strohbehn I, Lee M, Hobbs G, Keyzner A, Jhaveri KD, Sise ME. Acute kidney injury after ruxolitinib: Common complication, uncommon cause. Am J Hematol 2020; 95:E181-E183. PubMed
  • How J, Hobbs G, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood 2019. PubMed
  • Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer 2019. PubMed
  • Chen EC, Werner L, Hobbs GS, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma 2019. PubMed
  • Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol 2018. PubMed
  • Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer 2018. PubMed
  • DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 2018; 93:254-261. PubMed
  • Hobbs GS, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, McKenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal RK. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica 2018; 103:e5-e9. PubMed
  • Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv 2017; 1:2032-2040. PubMed
  • Jalbut MM, Brunner AM, Amrein PC, Ballen KK, Hobbs GS, Perry AM, Joseph CP, Fathi AT. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 2017. PubMed
  • Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2017; 31:613-626. PubMed
  • Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer 2017; 123:2561-2569. PubMed